Universität des Saarlandes

6 in Phase 3

Quick facts

Phase 3 pipeline

Alternative medications: carboplatin · Oncology
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.
Conventional Vincristine · Oncology
Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, causing cell cycle arrest in metaphase and triggering apoptosis in cancer cells.
optimised rituximab-schedule · Oncology, Immunology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
R-miniCHOP · Oncology
R-miniCHOP is a reduced-intensity chemotherapy regimen combining rituximab with a modified CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) backbone designed to treat lymphomas with lower toxicity.
R-miniCHOP + Acalabrutinib · Oncology
R-miniCHOP chemotherapy combined with acalabrutinib (a Bruton tyrosine kinase inhibitor) targets rapidly dividing lymphoma cells while blocking BTK signaling to enhance anti-tumor immunity.
Ricover-scheme rituximab · Oncology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduced antibody production in lymphoma and autoimmune conditions.

Phase 1 pipeline

Vancomycine · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Universität des Saarlandes

What is Universität des Saarlandes's pipeline?

Universität des Saarlandes has 6 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Alternative medications: carboplatin, Conventional Vincristine, optimised rituximab-schedule, R-miniCHOP.

Sector hub: All tracked pharma companies